Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HS-20122

Phase 1Small molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-20122 is one of 97 small molecule programs targeting Lung Cancer. It is currently in Phase 1.

3

Indications

3

Total Trials

3

Active Trials

96

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerRecruiting

Patients With Advanced Solid TumorsRecruiting

Phase IBNot yet recruiting

Lung CancerPhase 1

Recruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

Phase IBPhase 1

Not yet recruiting

Competition

Competitive Landscape

249 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Avastin

Gemzar

Johnson & Johnson

Eloxatin

Opdivo

Bristol-Myers Squibb

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Paraplatin

Lynparza

Tecentriq

Camptosar

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT06927570

Q4 2028

Phase 1Not yet recruiting

Phase IB

NCT07414953

Q2 2029

Phase 1Recruiting

Lung Cancer

NCT07645222

Clinical

Trials by Indication[1]

Phase IB1 trial

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT07414953·400 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of HS-20122 in Patients With Advanced Solid Tumors

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06927570·1,050 enrolled

Lung Cancer1 trial

A PHASE Ib STUDY OF THE SAFETY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF HS-20122 COMBINED THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS

Recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT07645222·396 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HS-20122. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-20122 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-20122. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Related News